Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.

Takiguchi K, Uezato A, Itasaka M, Atsuta H, Narushima K, Yamamoto N, Kurumaji A, Tomita M, Oshima K, Shoda K, Tamaru M, Nakataki M, Okazaki M, Ishiwata S, Ishiwata Y, Yasuhara M, Arima K, Ohmori T, Nishikawa T.

BMC Psychiatry. 2017 Jul 12;17(1):249. doi: 10.1186/s12888-017-1410-3.

2.

Glycine-Binding Site Stimulants of NMDA Receptors Alleviate Extrapyramidal Motor Disorders by Activating the Nigrostriatal Dopaminergic Pathway.

Shimizu S, Sogabe S, Yanagisako R, Inada A, Yamanaka M, Iha HA, Ohno Y.

Int J Mol Sci. 2017 Jul 3;18(7). pii: E1416. doi: 10.3390/ijms18071416.

3.

Animal models in psychiatric research: The RDoC system as a new framework for endophenotype-oriented translational neuroscience.

Anderzhanova E, Kirmeier T, Wotjak CT.

Neurobiol Stress. 2017 Mar 25;7:47-56. doi: 10.1016/j.ynstr.2017.03.003. eCollection 2017 Dec. Review.

4.

Effects of Augmenting N-Methyl-D-Aspartate Receptor Signaling on Working Memory and Experience-Dependent Plasticity in Schizophrenia: An Exploratory Study Using Acute d-cycloserine.

Forsyth JK, Bachman P, Mathalon DH, Roach BJ, Ye E, Asarnow RF.

Schizophr Bull. 2017 Sep 1;43(5):1123-1133. doi: 10.1093/schbul/sbw193.

PMID:
28338977
5.

Realising stratified psychiatry using multidimensional signatures and trajectories.

Joyce DW, Kehagia AA, Tracy DK, Proctor J, Shergill SS.

J Transl Med. 2017 Jan 18;15(1):15. doi: 10.1186/s12967-016-1116-1.

6.
7.

A randomized, placebo-controlled trial of D-cycloserine for the enhancement of social skills training in autism spectrum disorders.

Minshawi NF, Wink LK, Shaffer R, Plawecki MH, Posey DJ, Liu H, Hurwitz S, McDougle CJ, Swiezy NB, Erickson CA.

Mol Autism. 2016 Jan 14;7:2. doi: 10.1186/s13229-015-0062-8. eCollection 2016.

8.

D-Cycloserine in Neuropsychiatric Diseases: A Systematic Review.

Schade S, Paulus W.

Int J Neuropsychopharmacol. 2016 Apr 20;19(4). pii: pyv102. doi: 10.1093/ijnp/pyv102. Print 2016 Apr. Review.

9.

NMDA receptor activation regulates sociability by its effect on mTOR signaling activity.

Burket JA, Benson AD, Tang AH, Deutsch SI.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Jul 3;60:60-5. doi: 10.1016/j.pnpbp.2015.02.009. Epub 2015 Feb 20. Review.

10.

The impact of NMDA receptor hypofunction on GABAergic neurons in the pathophysiology of schizophrenia.

Cohen SM, Tsien RW, Goff DC, Halassa MM.

Schizophr Res. 2015 Sep;167(1-3):98-107. doi: 10.1016/j.schres.2014.12.026. Epub 2015 Jan 9. Review.

11.

Structural determinants and mechanism of action of a GluN2C-selective NMDA receptor positive allosteric modulator.

Khatri A, Burger PB, Swanger SA, Hansen KB, Zimmerman S, Karakas E, Liotta DC, Furukawa H, Snyder JP, Traynelis SF.

Mol Pharmacol. 2014 Nov;86(5):548-60. doi: 10.1124/mol.114.094516. Epub 2014 Sep 9.

12.

A trial of D-cycloserine to treat stereotypies in older adolescents and young adults with autism spectrum disorder.

Urbano M, Okwara L, Manser P, Hartmann K, Herndon A, Deutsch SI.

Clin Neuropharmacol. 2014 May-Jun;37(3):69-72. doi: 10.1097/WNF.0000000000000033.

13.

Magnetic resonance imaging in studying schizophrenia, negative symptoms, and the glutamate system.

Gruber O, Chadha Santuccione A, Aach H.

Front Psychiatry. 2014 Apr 3;5:32. doi: 10.3389/fpsyt.2014.00032. eCollection 2014. Review.

14.

d-Cycloserine augmentation of cognitive remediation in schizophrenia.

Cain CK, McCue M, Bello I, Creedon T, Tang DI, Laska E, Goff DC.

Schizophr Res. 2014 Mar;153(1-3):177-83. doi: 10.1016/j.schres.2014.01.016. Epub 2014 Jan 30.

15.

Adjunctive pharmacotherapy for cognitive deficits in schizophrenia: meta-analytical investigation of efficacy.

Choi KH, Wykes T, Kurtz MM.

Br J Psychiatry. 2013 Sep;203(3):172-8. doi: 10.1192/bjp.bp.111.107359. Review. Erratum in: Br J Psychiatry. 2013 Nov;203(5):392.

16.

Structure-activity relationships and pharmacophore model of a noncompetitive pyrazoline containing class of GluN2C/GluN2D selective antagonists.

Acker TM, Khatri A, Vance KM, Slabber C, Bacsa J, Snyder JP, Traynelis SF, Liotta DC.

J Med Chem. 2013 Aug 22;56(16):6434-56. doi: 10.1021/jm400652r. Epub 2013 Aug 2.

17.

Future perspectives on the treatment of cognitive deficits and negative symptoms in schizophrenia.

Goff DC.

World Psychiatry. 2013 Jun;12(2):99-107. doi: 10.1002/wps.20026.

18.

Towards medication-enhancement of cognitive interventions in schizophrenia.

Chou HH, Twamley E, Swerdlow NR.

Handb Exp Pharmacol. 2012;(213):81-111. doi: 10.1007/978-3-642-25758-2_4. Review.

19.

Failure of neural responses to safety cues in schizophrenia.

Holt DJ, Coombs G, Zeidan MA, Goff DC, Milad MR.

Arch Gen Psychiatry. 2012 Sep;69(9):893-903. doi: 10.1001/archgenpsychiatry.2011.2310.

20.

The 3rd Schizophrenia International Research Society Conference, 14-18 April 2012, Florence, Italy: summaries of oral sessions.

Abbs B, Achalia RM, Adelufosi AO, Aktener AY, Beveridge NJ, Bhakta SG, Blackman RK, Bora E, Byun MS, Cabanis M, Carrion R, Castellani CA, Chow TJ, Dmitrzak-Weglarz M, Gayer-Anderson C, Gomes FV, Haut K, Hori H, Kantrowitz JT, Kishimoto T, Lee FH, Lin A, Palaniyappan L, Quan M, Rubio MD, Ruiz de AzĂșa S, Sahoo S, Strauss GP, Szczepankiewicz A, Thompson AD, Trotta A, Tully LM, Uchida H, Velthorst E, Young JW, O'Shea A, Delisi LE.

Schizophr Res. 2012 Oct;141(1):e1-e24. doi: 10.1016/j.schres.2012.07.024. Epub 2012 Aug 19.

Supplemental Content

Support Center